Evaluation of the resistance to antiretroviral drugs. Review of the clinical trials published;Evaluatión de la resistencia a los fármacos antirretrovirícos. Publication de ensayos clínicos

Enfermedades Infecciosas y Microbiologia Clinica

Volumn 17, Issue SUPPL. 2, 1999, Pages 81-85

  Dalmau, David ^a   De Echagüen, Anna Ochoa ^a  

^a HOSPITAL MÚTUA DE TERRASSA   (Spain)

Author keywords

AIDS; Antiretrovirals; EBM; Genetic barrier; HIV; Resistance

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADULT; ANTIBIOTIC RESISTANCE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DOUBLE BLIND PROCEDURE; DRUG COMBINATION; EVIDENCE BASED MEDICINE; GENETICS; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFORMATION SERVICE; METHODOLOGY; MULTIDRUG RESISTANCE; MUTATION; RANDOMIZED CONTROLLED TRIAL; REVIEW; TREATMENT FAILURE; VIRUS LOAD;

ADULT; ANTI-HIV AGENTS; CLINICAL TRIALS; DOUBLE-BLIND METHOD; DRUG RESISTANCE, MICROBIAL; DRUG RESISTANCE, MULTIPLE; DRUG THERAPY, COMBINATION; EVIDENCE-BASED MEDICINE; GENOTYPE; HIV; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; INFORMATION SERVICES; MUTATION; RANDOMIZED CONTROLLED TRIALS; RESEARCH DESIGN; REVERSE TRANSCRIPTASE INHIBITORS; TREATMENT FAILURE; VIRAL LOAD;

EID: 0033256864     PISSN: 0213005X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Eigen M. Viral quasispecies. Sci Amm 1993; 269: 42-49.
2. Drake JW. Rates of spontaneous mutation among RNA viruses. Proc Natl acad Sci USA 1993; 90:4171-75.
3. Mansky LM, Temin HM. Lower in vivo mutation rate of human immunodeficiency virus type 1 than that predicted from the fidelity of purified reverse transcriptase. J Virol 1995; 69: 5087-94.
4. Perelson AS, Neumann AU, Markowitz M, Leonard JM, Ho DD. HIV-1 dynamics in vivo: Virion clearence rate, infected cell-life span and viral generation time. Science 1996; 271:1582-86.
5. Kunzi MS, Groopman JE. Identification of a novel human immunodeficiency virus strain cytopathic to megacaryocytic cells. Blood 1993; 81: 3336-42.
6. Connor RI, Ho DD. Human immunodeficiency virus type 1 variants with increased replicative capacity develop during the asymptomatic stage before disease progresion. J virol 1994; 68:4400-08.
7. Coffin JM. HIV population dynamics in vivo: Implications for genetic variation, Pathogenesis, and therapy. Science 1995; 267: 493-89.
8. Hirsch MS, Conway B, D'Aquila RT, Johnson VA, Brun-Vezinet F, Clotet B, Demeter LM, Hammer SM, Jacobsem DM, Kuritzkes DR, Loveday C, Mellors JW, Vella S, Richman DD. Antiretroviral drug resistance testing in adults with HIV infection. JAMA 1998; 279:1984-91.
9. Larder BA, Darby G, Richman DD. HIV with reduced sensitivity to Zidovudine isolate during prolonged therapy. Science 1989; 243:1731-34.
10. Larder BA, Kemp SD. Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT). Science 246; 1155-58.
11. Larder BA, Darby G, Richman DD. HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. Science, 1989 Mar, 243: 4899, 1731-4.
12. Molla A, Korneyeva M, Gao Q, Vasavanonda S, Schipper PJ, Mo HM, Markowitz M, Chernyavskiy T, Niu P, Lyons N, Hsu A, Granneman GR, Ho DD, Boucher CA, Leonard JM, Norbeck DW, Kempf DJ. Ordered accumulation of mutations in HIV protease confers resistance to ritonavir. Nat Med, 1996 Jul, 2:7, 760-6.
13. Condra JH, Schleif WA, Blahy OM, Gabryelski LJ, Graham DJ, Quintero JC, Rhodes A, Robbins HL, Roth E, Shivaprakash M, et al. In vivo emergence of HIV-1 variants resistent to multiples protease inhibitors. Nature, 1995, 374:569-71.
14. Wei X, Ghosh SK, Taylor ME, Johnson VA, Emini EA, Deutsch P, Lifson JD, Bonhoeffer S, Nowak MA, Hahn BH et al. Viral dynamics in human immunodeficiency virus type 1 infection. Nature, 1995 Jan, 373: 6510, 117-22.
15. Van Leeuwen R, Katlama C, Kitchen V, Boucher CA, Tubiana R, McBride M, Ingrand D, Weber J, Hill A, McDade H, et al. Evaluation of safety and eficacy of 3TC (lamivudine) in patients with asymptomatic or mildly asymptomatic human immunodeficiency virus infection: a fase I/II study. J Infec Dis, 1995; 171: 1166-71.
16. Havlir D, Hellmann N, Petropoulos C et al. Viral rebound in the presence of indinavir without protease inhibitor resistance. 6th Conference on Retroviruses and Opportunistic Infections, January-February 1999, Chicago. Abst. LB12.